Table 1.

Clinical Characteristics of the Participants

Local CohortUKB CasesUKB Controls
n3096111 283
Age at event, y*38.0 (35.3–39.0)39.0 (36.8–40.0)58.0 (51.0–63.0)
Sex (male), n/total (%)20/30 (66.7)77/96 (80.2)52 664/111 283 (47.3)
BMI, kg/m230.5 (28.1–32.7)29.3 (26.8–33.4)26.8 (24.3–30.0)
WHR0.95 (0.91–1.00)0.95 (0.89–0.99)0.88 (0.81–0.94)
Smoking at time of event, n/total (%)24/30 (80.0)78/95 (82.1)51 528/110 990 (46.4)
Hypertension, n/total (%)12/30 (40.0)61/96 (63.5)30 575/111 120 (27.5)
Diabetes mellitus, n/total (%)2/30 (6.7)15/95 (15.8)5796/111 057 (5.2)
Family history of CAD, first degree, n/total (%)18/30 (60.0)72/96 (75.0)48 536/111 015 (43.7)
Total cholesterol, mmol/L§5.19 (4.14–6.10)NANA
LDL cholesterol, mmol/L§3.17 (2.51–3.94)NANA
HDL cholesterol, mmol/L§0.86 (0.78–1.09)NANA
Triglycerides, mmol/L§2.01 (1.43–2.59)NANA
Cholesterol-lowering medication, n/total (%)5/30 (16.7)NANA
HbA1c (%)5.5 (5.3–5.8)NANA
Event, n/total (%)
 Stable CAD5/30 (16.7)NANA
 NSTEMI8/30 (26.7)NANA
 STEMI17/30 (56.7)NANA
No. of affected vessels, n/total (%)
 110/30 (33.3)NANA
 212/30 (40.0)NANA
 38/30 (26.7)NANA
Angioplasty, n/total (%)NA64/96 (66.7)1627/111 283 (1.5)
CABG, n/total (%)NA49/96 (51.0)848/111 283 (0.76)
Angioplasty and CABG, n/total (%)NA17/96 (17.7)116/111 283 (0.10)
  • Median (interquartile range) for continuous variables. Data unavailable in local cohort: BMI, 1 participant; WHR, 7 participants; Lipid profile, 1 participant; HbA1c, 5 participants. Data unavailable in UKB: BMI, 2 cases and 294 controls; WHR, 1 case and 169 controls. SI conversion factors: to convert cholesterol to mg/dL, multiply values by 38.61; to convert triglycerides to mg/dL, multiply values by 88.50. BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; HbA1c, glycohemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSTEMI, non–ST-segment–elevation myocardial infarction; STEMI, ST-segment–elevation myocardial infarction; UKB, UK Biobank cohort; and WHR, waist-to-hip ratio.

  • * Age that CAD was first diagnosed (self-report) for the UK Biobank cases and age of recruitment for the UK Biobank controls.

  • Previous or current smoking for the UKB (smoking status at the time of event was not available).

  • First-degree family history of CAD: man, <55 y and woman, <65 y in the local cohort; any history in the UKB (age was not available).

  • § In the local cohort, 9 of the 29 participants with available lipid profiles were on cholesterol-lowering medication at the moment of the measurement.

  • Cholesterol-lowering medication (statin, fibrate, or ezetimibe) at time of angiography.